“The collaboration with Entelos has generated candidate targets and biomarkers which will be pursued under the extension of our collaboration,” said David Nicholson, executive vice president for R&D at Organon.
Organon and Entelos have collaborated since 2001 to develop the Entelos Rheumatoid Arthritis PhysioLab platform, a large-scale, mathematical model that captures the overall disease process and allows the simulation of both current therapies and drugs in development.
Over 700 biological functions or pathways are included in the platform, enabling researchers to predict and evaluate clinical outcomes in response to therapeutic interventions and novel approaches in virtual patients spanning the wide range of real patients in the clinic.